復旦張江(01349.HK)上半年營收大增92.74%至5.23億元 淨利潤6843.8萬元
格隆匯8月10日丨復旦張江(01349.HK)公佈,截至2023年6月30日止六個月,實現公司股東應占該期利潤為人民幣6843.8萬元,去年同期則虧損為人民幣3597.5萬元,同比實現扭虧為盈。
公司報吿期內實現營業收入5.23億元,較上年同比增長92.74%。治療以尖鋭濕疣為代表的皮膚HPV感染性疾病和增生性疾病的艾拉®、治療腫瘤的裏葆多®及治療鮮紅斑痣的復美達®作為集團最重要的三大產品,對集團銷售醫藥及診斷產品的收入貢獻達到99.83%。
研發方面,集團堅持基於基因工程技術、光動力技術、納米技術和口服固體制劑技術平台的藥物開發方向,繼續採用針對選定藥物拓展新的臨牀適應症以及針對選定疾病繼續拓展新的藥物並設計出新的治療方案的研究模式,並適度向光動力藥物和抗體偶聯藥物兩個技術領域戰略性聚焦,形成具有競爭優勢的研發特色。報吿期內,集團的創新性研發領域主要集中在針對皮膚疾病、腫瘤和癌前病變的光動力藥物、針對腫瘤的抗體偶聯藥物、針對帕金森病全方位治療的緩控釋藥物。Me-too類藥物有針對自身免疫性疾病以及腫瘤的小分子靶向藥物以及擁有專利或技術壁壘的其它藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.